SCHEMBL4990875

SCHEMBL4990875

CCC(C)N1CCN(c2ccc(NC=C3C(=O)Nc4ccc(F)cc43)cc2C)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
NTRK1 P04629 2/20 0.39
FLT3 P36888 11/20 0.38
PDGFRB P09619 5/20 0.36
KDR P35968 5/20 0.36
TLK2 Q86UE8 3/20 0.36
FGFR1 P11362 3/20 0.36
CSF1R P07333 3/20 0.36
FLT1 P17948 3/20 0.36
KIT P10721 3/20 0.36
RIOK2 Q9BVS4 2/20 0.36
TLK1 Q9UKI8 2/20 0.36
CHEK1 O14757 2/20 0.36
ABL1 P00519 2/20 0.36
LCK P06239 2/20 0.36
FYN P06241 2/20 0.36
RET P07949 2/20 0.36
PHKG2 P15735 2/20 0.36
PDGFRA P16234 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4990869 1.00 MEN1 (0.40) MEN1KMT2ANTRK1FLT3PDGFRB
SCHEMBL4992227 0.93 TGM2 (0.40) MEN1KMT2ANTRK1FLT3PDGFRB
SCHEMBL4992232 0.93 TGM2 (0.40) MEN1KMT2ANTRK1FLT3PDGFRB
SCHEMBL4993093 0.92 NPY2R (0.42) MEN1KMT2ANTRK1FLT3NTRK3
SCHEMBL4993096 0.92 NPY2R (0.42) MEN1KMT2ANTRK1FLT3NTRK3
SCHEMBL4993221 0.88 MEN1 (0.38) MEN1KMT2ANTRK1FLT3PDGFRB
SCHEMBL4993216 0.88 MEN1 (0.38) MEN1KMT2ANTRK1FLT3PDGFRB
SCHEMBL4993957 0.86 MEN1 (0.46) MEN1KMT2ANTRK1FLT3PDGFRB
SCHEMBL4993961 0.86 MEN1 (0.46) MEN1KMT2ANTRK1FLT3PDGFRB
SCHEMBL4989022 0.85 MEN1 (0.45) MEN1KMT2ANTRK1FLT3PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414054-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2008-08-19 US disclosed
US-7098236-B2 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-08-29 US disclosed
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-03-23 US disclosed
US-7015220-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-03-21 US disclosed
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-02-02 US disclosed
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2005-10-13 US disclosed
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ANDREWS STEVEN W (US) 2004-10-07 US disclosed
US-6765012-B2 FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION ALLERGAN, INC. 2004-07-20 US disclosed
EP-1430048-A1 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS Allergan, Inc. (US) 2004-06-23 EP disclosed
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-12-04 US disclosed
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-10-23 US disclosed
WO-2003027102-A1 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN, INC. (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 MEN1 2745/4885KMT2A 958/4885NTRK1 294/4885
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 MEN1 2745/4885KMT2A 958/4885NTRK1 294/4885
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 MEN1 2745/4885KMT2A 958/4885NTRK1 294/4885
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 MEN1 2745/4885KMT2A 958/4885NTRK1 294/4885
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 MEN1 2745/4885KMT2A 958/4885NTRK1 294/4885
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 MEN1 2745/4885KMT2A 958/4885NTRK1 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.